Lung Injury Linked to Etanercept Therapy

Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab

“…These previous reports included 4 on granulomatous interstitial lung disease: in one report, the disease was due to Mycobacterium avium intracelullare (4), whereas in the other 3 reports, culture results revealed no microorganism (5-7). Four more cases involved patients treated with methotrexate who developed pneumonitis after initiation of infliximab (8,9).…”

Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy

“…15,17,18 Some reports have indicated the new development of rheumatoid nodules in the lung with etanercept therapy, while one report by Peno-Green et al 18 focused on new skin and lung lesions, reflecting a systemic non-necrotizing granulomatous process associated with microscopic particulates. The four cases in this report represent acute pulmonary reactions in patients with rheumatoid arthritis, which were temporally related to the institution of etanercept therapy.…”

“…[10][11][12][13][14] Pleuropulmonary manifestations of this therapy are rare with isolated reports of dyspnea, new onset of pulmonary rheumatoid nodulosis, and a systemic sarcoid-like granulomatous reaction. [15][16][17][18] This study details four cases of pulmonary disease associated with the institution of etanercept therapy, with the predominant manifestation being a granulomatous pneumonitis associated with an atypical lymphohistiocytic infiltrate.…”

Abrupt Development of Sarcoidosis with a Prodromal Increase in Plasma Osteopontin in a Patient with Rheumatoid Arthritis During Treatment with Etanercept

“…Reports show that infliximab is effective, while etanercept is not, in the treatment of sarcoidosis 1,2 . In contrast, anti-TNF-α agents may have induced sarcoidosis in patients with RA and spondyloarthropathy [3][4][5][6] .…”